The best finger-prick antibody tests take ten minutes and such diagnostic assessment is well within the official and permitted scope of practice of dentists (as the Care Quality Commission have directly indicated in their regular bulletins). The implications for dentistry can be logically summarised as follows: SARS-CoV-2 IgG antibody is directly linked to non-infectiousness noninfectious people need good universal PPE precautions, but not extra enhanced precautions for aerosol generating procedures IgG antibody fades over time, so the earlier after infection testing is done, the more likely they are to be positive – with helpful documentation of recent SARS-CoV-2 infection Vulnerable people who are currently denied access to routine/urgent dental treatment can be safely treated if shown to be noninfectious The longitudinal patient relationship in dentistry lends itself naturally to antibody testing and retesting, as well as for other services such as vaccine delivery, health screening and wider prevention services. It is also likely that assessment of continuing vaccine protection can be assessed with IgG antibody tests, and a neutralising IgG antibody is a key marker of vaccine responses, aligned with other immune parameters such as T cell responses. We need to use all Levosimendan the tools at our disposal for controlling SARS-CoV-2. of infectiousness than a repeat PCR which is only 70% sensitive. It remains to be seen whether SARS-Cov-2 vaccine responses include protective IgG titres and, once vaccines become widespread, can be used to assist decision-making on appropriate personal protective equipment (PPE) in dentistry. Key points SARS-CoV-2 viral infectivity lasts for eight days from the start of infection. SARS-CoV-2 IgG antibody is usually neutralising, is first detectable at 11 days after infection and persists for months. People with detectable SARS-CoV-2 IgG antibody can safely be Levosimendan regarded as noninfectious (>99% level of certainty). Introduction It is helpful for dentists (and other community healthcare professionals) to know who is not infectious for any pathogen, but especially highly transmissible ones such as SARS-CoV-2. Extraordinarily few studies have addressed the risk to dental professionals of respiratory viruses,1 and the efficacy of universal precautions (standard personal protective equipment [PPE]) versus various means of enhancing protection is not known. What is clear is that extra PPE precautions are unnecessary if the patient is known to be non-infectious. The immune response to SARS-CoV-2 is complex and changes during and after infection. Here, we describe the current state of knowledge regarding viral infectiousness, molecular (polymerase chain reaction [PCR] swab) testing, antibody production, clinical interpretation and immunity. We summarise the implications for dental practice. SARS-CoV-2 is the name of the coronavirus causing the symptomatic disease COVID-19; those with asymptomatic infection are best referred to as having SARS-CoV-2 infection. The course of SARS-CoV-2 infection After infection, SARS-CoV-2 viral load rises to maximum levels about two days before symptoms start and remains high for five days, then falls after 7-8 days2,3,4 (Fig. 1). Live virus is not culturable after eight days in non-immunocompromised people (work in Germany, Canada and France),2,3,4 consistent with transmission ceasing 6-8 days after symptom onset.5,6 Viral RNA remains detectable in mouth and nasal swabs, sputum and faeces for up to seven weeks,2,7 but it represents non-viable remnants of virus. Asymptomatic infected people probably have the Rabbit polyclonal to Prohibitin same viral trajectory, with slightly less virus on average. The amount of virus detectable in a given person on any given day varies enormously from around 100 virions to over 10,000,000,000 per sample.8 Open in a separate window Fig. 1 Summary of SARS-CoV-2 viral and PCR kinetics over time, compared with the IgM and IgG responses. There is much individual variation, but viable virus falls to zero in 7-10 days in all patients, apart from those who are immunocompromised. Image courtesy of DenScreen There is a single report of a heart transplant patient still growing the virus at five weeks after infection.9 So, immunocompromised individuals may excrete the virus for much longer and this key point in a medical history should be checked. The antibody response to SARS-CoV-2 The earliest antibody to appear in blood is SARS-CoV-2 immunoglobulin M (IgM), usually from day 5-7 after symptoms appear, but sometimes later.2,10,11,12,13 Not all patients produce IgM and the amount of IgM in blood rises rapidly and Levosimendan falls away earlier than immunoglobulin G (IgG). IgM antibody primarily functions as defence against gram-negative bacteria, but is a marker of infection against most pathogens. IgG and immunoglobulin A (IgA) production follows IgM, with these antibodies detectable from day 11 and reaching a maximum 3-4 weeks after infection.2,10,11,12,13 IgG and IgA antibody titres are highly correlated.10 IgA antibody protects mucosal surfaces from infection. Not all those with COVID-19 produce IgG or IgA. Antibodies are directed against several viral proteins: the surface spike protein (a glycoprotein), nucleocapsid phosphoprotein, membrane glycoprotein, envelope protein and several other nonstructural proteins.14 Most antibody tests.